SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doug Bean who wrote (1547)12/21/1999 2:53:00 PM
From: Firenze  Read Replies (1) of 1837
 
Doug,

The formulary issue is a very big deal. If Apri and Cenestin are on the formularies then plan members would be able to purchase the products at a copayment instead of the full price.

However, more insurers are moving to what is called a three-tier benefit plan where the third-tier is the highest copayment. Since both are usually less than $25 per Rx then most women in these plans will not be hit that bad in the pocket, as their out-of-pocket expense will be below their copayment

Firenze
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News